Medicover

* Q3'26 numbers due on 4 November at 07:45 CET * Estimate changes reflect India divestment * Fair value changed to SEK 220-300 (190-270) Q3'26 expectations Overall, we expect Medicover to perform broadly in line with Q2'26. As the Indian (MHI) divestment...

* Sells MHI to KKR; deal expected by management to close in Q4* Agreed EV of EUR 1.2bn corresponds to ~46x EV/EBITDA* Improves financial flexibility for European strategy The deal in brief Medicover today announced that it has agreed to divest its Indian...

* Q2 broadly in line across most line items * '26e-'28e adj. EBITDA -0.7%/-0.4%/-0.4% on weaker Romania * FVR unchanged at SEK 190-270 on minor estimate revisions Broadly in line, Romania weighs Revenue grew 7.3% y-o-y to EUR 640m, with org. growth acceleratin...

* -1%/0% adj. EBITDA vs ABGSCe/Infront cons in Q2 * Cons estimates likely unchanged * Trading at 10.2x '26e EV/EBITDA Q2 results: In line with expectations Medicover reported a second quarter in line with cons. Q2 sales were EUR 640m (0% vs ABGSCe, 0...

* Q2'26 numbers due on 22 July at 07:45 CET * Minor estimate changes, margins unchanged * Fair value range kept at SEK 190-270 Q2'26 expectations For Q2, we expect Medicover to perform broadly in line with Q1'26. In Poland and Romania, government funding...